Stocks Health care LLY
NYSE · Health careELI LILLY & Co (LLY)
ELI LILLY & Co brought in $79.7B of revenue over the twelve months to June 30, 2026, up 49.6% from a year earlier. Net income was $26.7B, a net margin of 33.5%. At June 30, 2026 it held $9B in cash against $47.9B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
What ELI LILLY & Co does
Eli Lilly and Company is a pharmaceutical company that discovers, develops, and sells prescription medicines. It produces treatments for diabetes, obesity, oncology, immunology, and neuroscience conditions. Its products are purchased by wholesalers, pharmacies, hospitals, and healthcare providers. The company is known for drugs such as Prozac, Humalog, and Mounjaro. Its shares trade on NYSE under the ticker LLY.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $65.2B | $20.6B | $22.95 | n/a |
| 2024 | $45B | $10.6B | $11.71 | n/a |
| 2023 | $34.1B | $5.2B | $5.80 | n/a |
| 2022 | $28.5B | $6.2B | $6.90 | n/a |
| 2021 | $28.3B | $5.6B | $6.12 | n/a |
| 2020 | $24.5B | $6.2B | $6.79 | n/a |
Latest SEC filings
What ELI LILLY & Co has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026
- August 5, 2026
- July 30, 2026Activist stake (5% or more) SCHEDULE 13D
- July 24, 2026Passive stake changed SCHEDULE 13G/A
- July 24, 2026Passive stake (5% or more) SCHEDULE 13G
- July 23, 2026Passive stake changed SCHEDULE 13G/A
- June 23, 2026
- June 2, 2026Delisting notice 25-NSE
- May 20, 2026Other event 8-K
- May 11, 2026
Questions about LLY
What does ELI LILLY & Co do?
Eli Lilly and Company is a pharmaceutical company that discovers, develops, and sells prescription medicines. It produces treatments for diabetes, obesity, oncology, immunology, and neuroscience conditions. Its products are purchased by wholesalers, pharmacies, hospitals, and healthcare providers. The company is known for drugs such as Prozac, Humalog, and Mounjaro. Its shares trade on NYSE under the ticker LLY.
Is ELI LILLY & Co profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $26.7B on revenue of $79.7B, a net margin of 33.5%.
How much revenue does ELI LILLY & Co make?
Over the twelve months to June 30, 2026 ELI LILLY & Co reported revenue of $79.7B. That is 49.6% more than a year earlier.
When did ELI LILLY & Co last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 22, 2026.
Similar companies
Follow LLY
Get an email when ELI LILLY & Co files with the SEC: results, executive changes, material agreements and annual reports.
Follow LLY: get an email when it filesWhere the numbers come from
Financial figures are the values ELI LILLY & Co tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.